Morningstar

Medtronic to Invest Up to $80 Million to Advance Structural Heart Portfolio

Provided by Dow Jones

By Connor Hart 




  Medtronic will make an up to $80 million strategic investment in Pi-Cardia, strengthening its structural heart portfolio and supporting the next generation of innovation. 



  "As structural heart care evolves, we're investing in technologies that help physicians address today's challenges while preparing for tomorrow's opportunities," said Jorie Soskin, who serves as vice president and general manager of Medtronic's Structural Heart business. 



  Pi-Cardia's ShortCut device is the first FDA-cleared leaflet modification technology designed to enable valve-in-valve, transcatheter aortic valve replacement procedures in patients at risk of coronary obstruction, according to Medtronic. 



  The company said the device provides physicians with a safe, easy-to-learn, reproducible approach to leaflet modification that can help preserve coronary access and enable future transcatheter valve procedures. 



  Under its agreement, Medtronic said it will become the exclusive global commercial distributor of the ShortCut device next year. The company will work to expand physician access across the U.S. and international markets. 



  The agreement also includes an option for Medtronic to acquire Pi-Cardia upon achievement of predefined milestones for an estimated upfront acquisition price of up to $210 million, the companies said. 





  Write to Connor Hart at connor.hart@wsj.com 





  (END) Dow Jones Newswires



  September 01, 2026 07:08 ET (11:08 GMT)


Copyright (c) 2026 Dow Jones & Company, Inc.
  

					The articles, information, and content displayed on this webpage may
					include materials prepared and provided by third parties. Such
					third-party content is offered for informational purposes only and
					is not endorsed, reviewed, or verified by Morningstar.
				
 

					Morningstar makes no representations or warranties regarding the
					accuracy, completeness, timeliness, or reliability of any third-party
					content displayed on this site. The views and opinions expressed in
					third-party content are those of the respective authors and do not
					necessarily reflect the views of Morningstar, its affiliates, or employees.
				
 

					Morningstar is not responsible for any errors, omissions, or delays
					in this content, nor for any actions taken in reliance thereon.
					Users are advised to exercise their own judgment and seek independent
					financial advice before making any decisions based on such content.
					The third-party providers of this content are not affiliated with
					Morningstar, and their inclusion on this site does not imply any
					form of partnership, agency, or endorsement.
				
 

				Popular
				
 
  
 
 
 
 
September Stock Market Outlook: How to Position Your Portfolio During a Risky Stage
 
Excluding just seven stocks from our valuation, the remaining market is trading at fair value. 
 
 
David Sekera, CFA 
 
 
 
Worried About a Stock Market Bubble? Here Are 5 Ways to Stay Invested
 
Here’s how concerned investors can participate in the US stock market while managing its risks. 
 
 
Dan Lefkovitz 
 
 
 
TIPS Look Tempting. Should You Buy?
 
Treasury Inflation-Protected Securities are sporting some of the highest yields ever, but there are a few caveats for investors to consider before making a purchase. 
 
 
Jeffrey Ptak, CFA 
 
 
 
3 Stocks to Sell and 3 Stocks to Buy for September
 
Plus, whether Nvidia, Marvell Technology, or Salesforce looks attractive after earnings. 
 
 
David Sekera, CFA and Susan Dziubinski 
 
 
 
If You’re Worried About Your Bond Portfolio, You’re Missing the Point
 
For the safe part of your portfolio, err on the side of caution and get out of the timing business. 
 
 
Christine Benz 
 
 
 
 

			Sponsor Center